We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LabCorp (LH) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
LabCorp (LH - Free Report) closed at $187.99 in the latest trading session, marking a +0.58% move from the prior day. This change outpaced the S&P 500's 0.96% loss on the day. At the same time, the Dow lost 0.48%, and the tech-heavy Nasdaq lost 2.22%.
Prior to today's trading, shares of the medical laboratory operator had gained 6.98% over the past month. This has outpaced the Medical sector's loss of 0.24% and the S&P 500's loss of 4.04% in that time.
LH will be looking to display strength as it nears its next earnings release, which is expected to be October 27, 2020. On that day, LH is projected to report earnings of $4.77 per share, which would represent year-over-year growth of 64.48%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.71 billion, up 26.73% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.05 per share and revenue of $12.84 billion. These totals would mark changes of +24.12% and +11.1%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for LH. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.52% higher. LH is currently a Zacks Rank #3 (Hold).
Looking at its valuation, LH is holding a Forward P/E ratio of 13.3. This valuation marks a discount compared to its industry's average Forward P/E of 33.29.
We can also see that LH currently has a PEG ratio of 1.55. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Dental Supplies industry currently had an average PEG ratio of 2.78 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 119, which puts it in the top 48% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
LabCorp (LH) Gains As Market Dips: What You Should Know
LabCorp (LH - Free Report) closed at $187.99 in the latest trading session, marking a +0.58% move from the prior day. This change outpaced the S&P 500's 0.96% loss on the day. At the same time, the Dow lost 0.48%, and the tech-heavy Nasdaq lost 2.22%.
Prior to today's trading, shares of the medical laboratory operator had gained 6.98% over the past month. This has outpaced the Medical sector's loss of 0.24% and the S&P 500's loss of 4.04% in that time.
LH will be looking to display strength as it nears its next earnings release, which is expected to be October 27, 2020. On that day, LH is projected to report earnings of $4.77 per share, which would represent year-over-year growth of 64.48%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.71 billion, up 26.73% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.05 per share and revenue of $12.84 billion. These totals would mark changes of +24.12% and +11.1%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for LH. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.52% higher. LH is currently a Zacks Rank #3 (Hold).
Looking at its valuation, LH is holding a Forward P/E ratio of 13.3. This valuation marks a discount compared to its industry's average Forward P/E of 33.29.
We can also see that LH currently has a PEG ratio of 1.55. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Dental Supplies industry currently had an average PEG ratio of 2.78 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 119, which puts it in the top 48% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.